Wockhardt's Investigational Drug, Zaynich, Cures Complex Case of Meningitis Caused by Pan-Drug Resistant Super-Bug
Wockhardt's investigational drug, Zaynich (Zidebactam/Cefepime), has successfully treated over 35 critically ill patients in India and US who were suffering from extremely drug-resistant infections under compassionate use. A recent case involved a 64-year-old patient with Type 2 diabetes and hypertension, who had been battling pulmonary and meningeal tuberculosis for about a year. Following a spinal puncture, the patient developed bacterial meningitis caused by a pan-drug resistant super-bug, Pseudomonas. Initial treatments failed, but Zidebactam/Cefepime administered for three weeks led to the patient's recovery. The drug was well-tolerated and demonstrated its effectiveness in managing complex, deep-seated infections, particularly in difficult-to-treat body sites like the brain and spinal cord.
Key Highlights
- Wockhardt's investigational drug, Zaynich, has treated over 35 critically ill patients in India and US under compassionate use.
- The drug has shown effectiveness in managing complex, deep-seated infections, particularly in difficult-to-treat body sites.
- A recent case involved a 64-year-old patient with Type 2 diabetes and hypertension who had been battling pulmonary and meningeal tuberculosis for about a year.
- Initial treatments with Ceftazidime/Avibactam, Aztreonam, and Meropenem failed to halt the patient's deterioration.
- Zidebactam/Cefepime led to the patient's recovery, demonstrating its remarkable ability to tackle infections in difficult-to-treat body sites.